Literature DB >> 11895152

Pyruvate kinase type M2: a crossroad in the tumor metabolome.

S Mazurek1, H Grimm, C B Boschek, P Vaupel, E Eigenbrodt.   

Abstract

Cell proliferation is a process that consumes large amounts of energy. A reduction in the nutrient supply can lead to cell death by ATP depletion, if cell proliferation is not limited. A key sensor for this regulation is the glycolytic enzyme pyruvate kinase, which determines whether glucose carbons are channelled to synthetic processes or used for glycolytic energy production. In unicellular organisms pyruvate kinase is regulated by ATP, ADP and AMP, by ribose 5-P, the precursor of the nucleic acid synthesis, and by the glycolytic intermediate fructose 1,6-P2 (FBP), thereby adapting cell proliferation to nutrient supply. The mammalian pyruvate kinase isoenzyme type M2 (M2-PK) displays the same kinetic properties as the pyruvate kinase enzyme from unicellular organisms. The mammalian M2-PK isoenzyme can switch between a less active dimeric form and a highly active tetrameric form which regulates the channeling of glucose carbons either to synthetic processes (dimeric form) or to glycolytic energy production (tetrameric form). Tumor cells are usually characterized by a high amount of the dimeric form leading to a strong accumulation of all glycolytic phosphometabolites above pyruvate kinase. The tetramer-dimer ratio is regulated by ATP, FBP and serine and by direct interactions with different oncoproteins (pp60v-src, HPV-16 E7). In solid tumors with sufficient oxygen supply pyruvate is supplied by glutaminolysis. Pyruvate produced in glycolysis and glutaminolysis is used for the synthesis of lactate, glutamate and fatty acids thereby releasing the hydrogen produced in the glycolytic glyceraldehyde 3-phosphate dehydrogenase reaction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895152

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  51 in total

Review 1.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

Review 2.  Human pyruvate kinase M2: a multifunctional protein.

Authors:  Vibhor Gupta; Rameshwar N K Bamezai
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

Review 3.  Pyruvate kinase: Function, regulation and role in cancer.

Authors:  William J Israelsen; Matthew G Vander Heiden
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

4.  Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase.

Authors:  Stefan Siwko; Daria Mochly-Rosen
Journal:  Int J Biochem Cell Biol       Date:  2007-01-24       Impact factor: 5.085

5.  Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Authors:  M D Landis; D D Seachrist; F W Abdul-Karim; R A Keri
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

6.  Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.

Authors:  Cristina Zaccaro; Ilaria Maria Saracino; Giulia Fiorini; Natale Figura; John Holton; Valentina Castelli; Valeria Pesci; Luigi Gatta; Dino Vaira
Journal:  Intern Emerg Med       Date:  2017-02-02       Impact factor: 3.397

Review 7.  Metabolic checkpoints in activated T cells.

Authors:  Ruoning Wang; Douglas R Green
Journal:  Nat Immunol       Date:  2012-09-18       Impact factor: 25.606

8.  Small molecule activation of PKM2 in cancer cells induces serine auxotrophy.

Authors:  Charles Kung; Jeff Hixon; Sung Choe; Kevin Marks; Stefan Gross; Erin Murphy; Byron DeLaBarre; Giovanni Cianchetta; Shalini Sethumadhavan; Xiling Wang; Shunqi Yan; Yi Gao; Cheng Fang; Wentao Wei; Fan Jiang; Shaohui Wang; Kevin Qian; Jeff Saunders; Ed Driggers; Hin Koon Woo; Kaiko Kunii; Stuart Murray; Hua Yang; Katharine Yen; Wei Liu; Lewis C Cantley; Matthew G Vander Heiden; Shinsan M Su; Shengfang Jin; Francesco G Salituro; Lenny Dang
Journal:  Chem Biol       Date:  2012-09-21

9.  PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.

Authors:  Wenjuan Li; Joan Liu; Yunfeng Zhao
Journal:  Mol Carcinog       Date:  2012-12-19       Impact factor: 4.784

10.  Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.

Authors:  Oluf Dimitri Røe; Endre Anderssen; Eli Helge; Caroline Hild Pettersen; Karina Standahl Olsen; Helmut Sandeck; Rune Haaverstad; Steinar Lundgren; Erik Larsson
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.